RxDoctor Payments DataLook up a doctor →

Ashish Trivedi, MD

Neurology · Auburn, WANPI 1134177413

Payments from drug & device makers

$140,153in general payments, 2019–2025

Across 1,446 payments — averaging $96.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$38K
  • Acadia Pharmaceuticals Inc$19K
  • Neurocrine Biosciences, Inc.$17K
  • EMD Serono, Inc.$13K
  • Bristol Myers Squibb$13K
  • SK Life Science, Inc.$6K
  • plus $33K from 54 others
$34,000in research payments, 2019–2025

Across 6 payments — averaging $5666.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$34K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC191$38,470
Acadia Pharmaceuticals Inc43$19,077
Neurocrine Biosciences, Inc.87$17,321
EMD Serono, Inc.177$12,958
Bristol Myers Squibb64$12,506
SK Life Science, Inc.25$6,271
E.r. Squibb & Sons, L.L.C.10$5,501
Eisai Inc.18$5,160
Neurelis, Inc.26$4,101
Biogen52$2,361
AbbVie(2 entities)89$1,612
Kyowa Kirin, Inc.19$1,421
Novartis65$1,356
Teva Pharmaceuticals USA, Inc.53$1,277
Sanofi32$923
Janssen Scientific Affairs, LLC4$887
Lundbeck LLC58$855
AstraZeneca47$798
Acorda Therapeutics, Inc33$546
UCB, Inc.21$533
Amgen36$514
Amneal Pharmaceuticals LLC31$478
Genentech USA, Inc.19$450
CSL Behring23$428
Johnson & Johnson(2 entities)23$333
Merz Pharmaceuticals, LLC11$304
TG Therapeutics, Inc.11$302
Pfizer15$287
Otsuka America Pharmaceutical, Inc.13$232
Takeda Pharmaceuticals U.S.A., Inc.7$222
Biohaven Pharmaceuticals, Inc.10$210
Vanda Pharmaceuticals Inc.6$172
Vertical Pharmaceuticals, LLC9$167
Argenx US, Inc.8$167
Sumitomo Pharma America, Inc.17$164
Boston Scientific2$163
Bausch Health US, LLC10$152
Alnylam Pharmaceuticals Inc.6$145
Supernus Pharmaceuticals, Inc.9$142
Arbor Pharmaceuticals, Inc.7$104
Avanir Pharmaceuticals, Inc.6$92
Banner Life Sciences, LLC5$82
MDD US Operations, LLC4$77
Biohaven Pharmaceutical Holding Company Ltd.4$74
Azurity Pharmaceuticals, Inc.4$72
Catalyst Pharmaceuticals, Inc.4$68
GE HealthCare3$66
Axsome Therapeutics, Inc.3$64
Ipsen Biopharmaceuticals, Inc2$46
Octapharma USA, Inc.2$42
Mallinckrodt Enterprises LLC2$36
Avion Pharmaceuticals2$36
Avadel CNS Pharmaceuticals, LLC1$32
Merz North America, Inc.1$29
Zogenix Inc.2$28
Amylyx Pharmaceuticals, Inc.1$24
Upsher-smith Laboratories LLC1$21
Otsuka Pharmaceutical Development & Commercialization, Inc.1$21
Nevro Corp.1$19
Zyla Life Sciences, Inc.1$17

How this compares

$140,153 in reported general payments places this provider in the 90th percentile of 418 neurology providers in Washington.

See all neurology providers in Washington →

Medicare billing

Part B allowed, 2024
$341,963
Medicare patients
564
Services billed
8,891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Auburn

See the full list for Washington →

Where these figures come from

Is this you, or does something look wrong? →